We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
Read MoreHide Full Article
Have you assessed how the international operations of NovoCure (NVCR - Free Report) performed in the quarter ended September 2026? For this oncology drug developer, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.
The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.
Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.
While analyzing NVCR's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter amounted to $193.4 million, showing rise of 15.7%. We will now explore the breakdown of NVCR's overseas revenue to assess the impact of its international operations.
Decoding NVCR's International Revenue Trends
During the quarter, Geographic revenues- France contributed $18.72 million in revenue, making up 9.7% of the total revenue. When compared to the consensus estimate of $19.75 million, this meant a surprise of -5.21%. Looking back, Geographic revenues- France contributed $21.35 million, or 11.6%, in the previous quarter, and $19.62 million, or 11.7%, in the same quarter of the previous year.
Of the total revenue, $24.95 million came from Geographic Revenues- Germany during the last fiscal quarter, accounting for 12.9%. This represented a surprise of +4.87% as analysts had expected the region to contribute $23.79 million to the total revenue. In comparison, the region contributed $23.34 million, or 12.7%, and $20.29 million, or 12.1%, to total revenue in the previous and year-ago quarters, respectively.
Geographic Revenues- Other international markets generated $18.82 million in revenues for the company in the last quarter, constituting 9.7% of the total. This represented a surprise of +2.01% compared to the $18.45 million projected by Wall Street analysts. Comparatively, in the previous quarter, Geographic Revenues- Other international markets accounted for $18.21 million (9.9%), and in the year-ago quarter, it contributed $15.71 million (9.4%) to the total revenue.
Greater China accounted for 2.3% of the company's total revenue during the quarter, translating to $4.49 million. Revenues from this region represented a surprise of +21.63%, with Wall Street analysts collectively expecting $3.69 million. When compared to the preceding quarter and the same quarter in the previous year, Greater China contributed $5.96 million (3.2%) and $5.6 million (3.4%) to the total revenue, respectively.
During the quarter, Japan contributed $14.52 million in revenue, making up 7.5% of the total revenue. When compared to the consensus estimate of $12.56 million, this meant a surprise of +15.6%. Looking back, Japan contributed $11.78 million, or 6.4%, in the previous quarter, and $9.39 million, or 5.6%, in the same quarter of the previous year.
Revenue Forecasts for the International Markets
Wall Street analysts expect NovoCure to report $188.9 million in total revenue for the current fiscal quarter, indicating an increase of 8.4% from the year-ago quarter. Geographic revenues- France, Geographic Revenues- Germany, Geographic Revenues- Other international markets, Greater China and Japan are expected to contribute 10.3% (translating to $19.54 million), 13.4% ($25.35 million), 10.1% ($19.12 million), 2% ($3.78 million), and 8.1% ($15.32 million) to the total revenue, respectively.
For the full year, the company is projected to achieve a total revenue of $732.62 million, which signifies a rise of 11.8% from the last year. The share of this revenue from various regions is expected to be: Geographic revenues- France at 11.3% ($82.49 million), Geographic Revenues- Germany at 13.4% ($98.15 million), Geographic Revenues- Other international markets at 9.8% ($71.83 million), Greater China at 2.6% ($19.01 million), and Japan at 7.1% ($51.86 million).
The Bottom Line
The dependency of NovoCure on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.
In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.
We at Zacks strongly focus on the dynamic earnings forecast of companies, given that empirical studies have demonstrated its potent impact on the immediate price movement of stocks. Invariably, there's a positive relationship -- upward earnings predictions often result in an increase in stock prices.
With an impressive externally audited track record, our proprietary stock rating tool - the Zacks Rank - harnesses the power of earnings estimate revisions and serves as an effective indicator of a stock's near-term price performance.
Over the past month, the stock has lost 12% versus the Zacks S&P 500 composite's 0.9% decrease. The Zacks Medical sector, of which NovoCure is a part, has risen 8.2% over the same period. The company's shares have declined 19.8% over the past three months compared to the S&P 500's 2.2% increase. Over the same period, the sector has risen 8.2%
View the Zacks #1 Rank List
Image: Bigstock
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
Have you assessed how the international operations of NovoCure (NVCR - Free Report) performed in the quarter ended September 2026? For this oncology drug developer, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.
The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.
Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.
While analyzing NVCR's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter amounted to $193.4 million, showing rise of 15.7%. We will now explore the breakdown of NVCR's overseas revenue to assess the impact of its international operations.
Decoding NVCR's International Revenue Trends
During the quarter, Geographic revenues- France contributed $18.72 million in revenue, making up 9.7% of the total revenue. When compared to the consensus estimate of $19.75 million, this meant a surprise of -5.21%. Looking back, Geographic revenues- France contributed $21.35 million, or 11.6%, in the previous quarter, and $19.62 million, or 11.7%, in the same quarter of the previous year.
Of the total revenue, $24.95 million came from Geographic Revenues- Germany during the last fiscal quarter, accounting for 12.9%. This represented a surprise of +4.87% as analysts had expected the region to contribute $23.79 million to the total revenue. In comparison, the region contributed $23.34 million, or 12.7%, and $20.29 million, or 12.1%, to total revenue in the previous and year-ago quarters, respectively.
Geographic Revenues- Other international markets generated $18.82 million in revenues for the company in the last quarter, constituting 9.7% of the total. This represented a surprise of +2.01% compared to the $18.45 million projected by Wall Street analysts. Comparatively, in the previous quarter, Geographic Revenues- Other international markets accounted for $18.21 million (9.9%), and in the year-ago quarter, it contributed $15.71 million (9.4%) to the total revenue.
Greater China accounted for 2.3% of the company's total revenue during the quarter, translating to $4.49 million. Revenues from this region represented a surprise of +21.63%, with Wall Street analysts collectively expecting $3.69 million. When compared to the preceding quarter and the same quarter in the previous year, Greater China contributed $5.96 million (3.2%) and $5.6 million (3.4%) to the total revenue, respectively.
During the quarter, Japan contributed $14.52 million in revenue, making up 7.5% of the total revenue. When compared to the consensus estimate of $12.56 million, this meant a surprise of +15.6%. Looking back, Japan contributed $11.78 million, or 6.4%, in the previous quarter, and $9.39 million, or 5.6%, in the same quarter of the previous year.
Revenue Forecasts for the International Markets
Wall Street analysts expect NovoCure to report $188.9 million in total revenue for the current fiscal quarter, indicating an increase of 8.4% from the year-ago quarter. Geographic revenues- France, Geographic Revenues- Germany, Geographic Revenues- Other international markets, Greater China and Japan are expected to contribute 10.3% (translating to $19.54 million), 13.4% ($25.35 million), 10.1% ($19.12 million), 2% ($3.78 million), and 8.1% ($15.32 million) to the total revenue, respectively.For the full year, the company is projected to achieve a total revenue of $732.62 million, which signifies a rise of 11.8% from the last year. The share of this revenue from various regions is expected to be: Geographic revenues- France at 11.3% ($82.49 million), Geographic Revenues- Germany at 13.4% ($98.15 million), Geographic Revenues- Other international markets at 9.8% ($71.83 million), Greater China at 2.6% ($19.01 million), and Japan at 7.1% ($51.86 million).
The Bottom Line
The dependency of NovoCure on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.
In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.
We at Zacks strongly focus on the dynamic earnings forecast of companies, given that empirical studies have demonstrated its potent impact on the immediate price movement of stocks. Invariably, there's a positive relationship -- upward earnings predictions often result in an increase in stock prices.
With an impressive externally audited track record, our proprietary stock rating tool - the Zacks Rank - harnesses the power of earnings estimate revisions and serves as an effective indicator of a stock's near-term price performance.
At the moment, NovoCure has a Zacks Rank #2 (Buy), signifying that it may outperform the overall market trend in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
NovoCure's Recent Stock Market Performance
Over the past month, the stock has lost 12% versus the Zacks S&P 500 composite's 0.9% decrease. The Zacks Medical sector, of which NovoCure is a part, has risen 8.2% over the same period. The company's shares have declined 19.8% over the past three months compared to the S&P 500's 2.2% increase. Over the same period, the sector has risen 8.2%